abrdn Life Sciences Investors Overview
Get informed when a big investor buys or sells
+ Follow33.16%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for HQL is 33.16%. That is above the sector sector average of 11.85%. Investors often review this figure alongside abrdn Life Sciences Investors's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, HQL currently prints 33.16% for ROE, while the sector average sits near 11.85%. That is roughly 179.8% above the sector mean. Large gaps often invite a closer look at abrdn Life Sciences Investors's growth, margins, and balance sheet.
Return on Equity shows how effectively abrdn Life Sciences Investors converts resources into returns. At 33.16%, HQL may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting HQL's ROE (33.16%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
